{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:33:03Z","timestamp":1792715583143,"version":"4.5.0"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2026,8,18]]},"abstract":"\n Importance<\/jats:title>\n Lower estimated glomerular filtration rate (eGFR) is associated with increased rates of death and kidney and cardiovascular events. Associations of measured GFR (mGFR) with outcomes remain unclear.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To quantify associations between mGFR and adverse clinical outcomes and to compare these with eGFR-based associations.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n Retrospective observational cohort study of 6174 adults from Stockholm, Sweden, between January 1, 2011, and December 31, 2021.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Measured GFR was obtained based on plasma clearance of intravenously administered iohexol (primary independent variable of interest). Estimated GFR was calculated with plasma creatinine (eGFRcr), cystatin C (eGFRcys), or both (eGFRcr-cys), using the Chronic Kidney Disease Epidemiology Collaboration 2021 and 2012 equations.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Primary outcomes were all-cause mortality and kidney failure with replacement therapy. Associations of each GFR measure with outcomes were evaluated using hazard ratios adjusted for age, sex, body mass index (calculated as weight in kilograms divided by height in meters squared), medical history, medications, and urine albumin to creatinine ratio.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 6174 participants (median age, 59 years [IQR, 43-69]; 3686 [60%] were male and 2488 [40%] were female), 1977 (32%) died and 426 (6.9%) developed kidney failure with replacement therapy during a median follow-up of 5.9 years (IQR, 3.0-8.8 years). Compared with a baseline mGFR of 90 mL\/min\/1.73 m\n 2<\/jats:sup>\n , an mGFR of 60 mL\/min\/1.73 m\n 2<\/jats:sup>\n was associated with higher rates of all-cause mortality (27.6 vs 22.4 per 1000 person-years; hazard ratio [HR], 1.21; 95% CI, 1.14-1.28) and kidney failure with replacement therapy (1.2 vs 0.4 per 1000 person-years; HR, 2.85; 95% CI, 2.06-3.94). For all-cause mortality, associations for eGFRcr-cys did not significantly differ from those for mGFR (ratio of HRs [RHRs] at 60 mL\/min\/1.73 m\n 2<\/jats:sup>\n , 1.03; 95% CI, 0.96-1.10), whereas eGFRcr underestimated the mGFR-based association (RHR, 0.87; 95% CI, 0.79-0.95) and eGFRcys overestimated it (RHR, 1.17; 95% CI, 1.08-1.27).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n \n Among adults in Sweden, mGFR values of 60 mL\/min\/1.73 m\n 2<\/jats:sup>\n were associated with higher rates of all-cause mortality and kidney failure compared with mGFR values of 90 mL\/min\/1.73 m\n 2<\/jats:sup>\n , supporting the current GFR threshold of 60 mL\/min\/1.73 m\n 2<\/jats:sup>\n to define chronic kidney disease. Associations of mGFR with mortality were most closely represented by the association of eGFRcr-cys with mortality, whereas eGFRcr underestimated and eGFRcys overestimated mortality risk.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2026.9639","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:30:20Z","timestamp":1780572620000},"page":"565","source":"Crossref","is-referenced-by-count":6,"title":["Measured and Estimated Glomerular Filtration Rates and Risk of Adverse Health Outcomes"],"prefix":"10.1001","volume":"336","author":[{"given":"Edouard L.","family":"Fu","sequence":"first","affiliation":[{"name":"Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands"},{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Cr\u00e9on","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan E.","family":"Grams","sequence":"additional","affiliation":[{"name":"Division of Precision Medicine, Department of Medicine, New York University Grossman School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Coresh","sequence":"additional","affiliation":[{"name":"Optimal Aging Institute, New York University Grossman School of Medicine, New York"},{"name":"Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland"},{"name":"Division of Epidemiology, Department of Population Health, New York University Grossman School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvid","family":"Sj\u00f6lander","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Faucon","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"Estrella","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, University of California, San Francisco"},{"name":"Renal Section, Medical Service, San Francisco VA Health Care System, San Francisco, California"},{"name":"Kidney Health Research Collaborative, Department of Medicine, San Francisco Veterans Affairs Health Care System and University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedo W.","family":"Dekker","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Shlipak","sequence":"additional","affiliation":[{"name":"Kidney Health Research Collaborative, Department of Medicine, San Francisco Veterans Affairs Health Care System and University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley A.","family":"Inker","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Levey","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan-Jesus","family":"Carrero","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden"},{"name":"Division of Nephrology, Department of Clinical Sciences, Karolinska Institute, Danderyd Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4S","key":"joi260063r1","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease.","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"issue":"22","key":"joi260063r2","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1056\/NEJMra2201153","article-title":"Uses of GFR and albuminuria level in acute and chronic kidney disease.","volume":"386","author":"Levey","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"joi260063r3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ki.2010.483","article-title":"The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report.","volume":"80","author":"Levey","year":"2011","journal-title":"Kidney Int"},{"issue":"9731","key":"joi260063r4","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.","volume":"375","author":"Matsushita","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"joi260063r5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/ki.2010.531","article-title":"Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes: a collaborative meta-analysis of general and high-risk population cohorts.","volume":"80","author":"Gansevoort","year":"2011","journal-title":"Kidney Int"},{"issue":"12","key":"joi260063r6","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/ki.2010.550","article-title":"Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease: a collaborative meta-analysis of kidney disease population cohorts.","volume":"79","author":"Astor","year":"2011","journal-title":"Kidney Int"},{"issue":"12","key":"joi260063r7","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/ki.2010.536","article-title":"Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality: a collaborative meta-analysis of high-risk population cohorts.","volume":"79","author":"van der Velde","year":"2011","journal-title":"Kidney Int"},{"issue":"13","key":"joi260063r8","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2023.17002","article-title":"Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis.","volume":"330","author":"Grams","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"joi260063r9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41581-019-0191-y","article-title":"Measured and estimated glomerular filtration rate: current status and future directions.","volume":"16","author":"Levey","year":"2020","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"joi260063r10","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1053\/j.ajkd.2021.04.016","article-title":"Measurement and estimation of GFR for use in clinical practice: Core Curriculum 2021.","volume":"78","author":"Inker","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"joi260063r11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.7326\/M23-1138","article-title":"Association of low glomerular filtration rate with adverse outcomes at older age in a large population with routinely measured cystatin C.","volume":"177","author":"Fu","year":"2024","journal-title":"Ann Intern Med"},{"issue":"3","key":"joi260063r12","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/joim.13418","article-title":"The Stockholm CREAtinine Measurements (SCREAM) project: fostering improvements in chronic kidney disease care.","volume":"291","author":"Carrero","year":"2022","journal-title":"J Intern Med"},{"issue":"9","key":"joi260063r13","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","article-title":"The Swedish cause of death register.","volume":"32","author":"Brooke","year":"2017","journal-title":"Eur J Epidemiol"},{"issue":"7","key":"joi260063r14","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/pds.1294","article-title":"The new Swedish Prescribed Drug Register\u2014opportunities for pharmacoepidemiological research and experience from the first six months.","volume":"16","author":"Wettermark","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"joi260063r15","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf238","article-title":"The Swedish Renal Registry: a nationwide registry for chronic kidney disease of all stages.","volume":"18","author":"Faucon","year":"2025","journal-title":"Clin Kidney J"},{"issue":"8","key":"joi260063r16","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1093\/ckj\/sfab042","article-title":"Assessment of kidney function: clinical indications for measured GFR.","volume":"14","author":"Ebert","year":"2021","journal-title":"Clin Kidney J"},{"issue":"19","key":"joi260063r17","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C\u2013based equations to estimate GFR without race.","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"joi260063r18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C.","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"joi260063r20","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1093\/ckj\/sfw070","article-title":"Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review, part 1: how to measure glomerular filtration rate with iohexol?","volume":"9","author":"Delanaye","year":"2016","journal-title":"Clin Kidney J"},{"issue":"4","key":"joi260063r21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.1475-097X.1983.tb00712.x","article-title":"A method for the calculation of renal clearance based on a single plasma sample.","volume":"3","author":"Jacobsson","year":"1983","journal-title":"Clin Physiol"},{"issue":"11","key":"joi260063r22","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1515\/CCLM.2010.318","article-title":"First certified reference material for cystatin C in human serum ERM-DA471\/IFCC.","volume":"48","author":"Grubb","year":"2010","journal-title":"Clin Chem Lab Med"},{"issue":"4","key":"joi260063r23","first-page":"251","article-title":"Did creatinine standardization give benefits to the evaluation of glomerular filtration rate?","volume":"28","author":"Pi\u00e9roni","year":"2017","journal-title":"EJIFCC"},{"issue":"12","key":"joi260063r24","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1093\/ckj\/sfac182","article-title":"Standardization of serum creatinine is essential for accurate use of unbiased estimated GFR equations: evidence from three cohorts matched on renal function.","volume":"15","author":"Pottel","year":"2022","journal-title":"Clin Kidney J"},{"issue":"8","key":"joi260063r26","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1001\/jama.2011.163","article-title":"Index event bias as an explanation for the paradoxes of recurrence risk research.","volume":"305","author":"Dahabreh","year":"2011","journal-title":"JAMA"},{"issue":"4","key":"joi260063r28","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/asaf059","article-title":"Resampling methods with multiply imputed data.","volume":"112","author":"Robbins","year":"2025","journal-title":"Biometrika"},{"issue":"1","key":"joi260063r29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ndt\/gfac254","article-title":"What should European nephrology do with the new CKD-EPI equation?","volume":"38","author":"Gansevoort","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"joi260063r30","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate.","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"2","key":"joi260063r31","doi-asserted-by":"publisher","first-page":"183","DOI":"10.7326\/M20-4366","article-title":"Development and validation of a modified full age spectrum creatinine-based equation to estimate glomerular filtration rate: a cross-sectional analysis of pooled data.","volume":"174","author":"Pottel","year":"2021","journal-title":"Ann Intern Med"},{"issue":"4","key":"joi260063r32","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJMoa2203769","article-title":"Cystatin C\u2013based equation to estimate GFR without the inclusion of race and sex.","volume":"388","author":"Pottel","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"joi260063r33","doi-asserted-by":"publisher","first-page":"426","DOI":"10.7326\/M20-0529","article-title":"Conversion of urine protein\u2013creatinine ratio or urine dipstick protein to urine albumin\u2013creatinine ratio for use in chronic kidney disease screening and prognosis: an individual participant-based meta-analysis.","volume":"173","author":"Sumida","year":"2020","journal-title":"Ann Intern Med"},{"key":"joi260063r34","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000001108","article-title":"Medications influencing serum cystatin C independent of measured glomerular filtration rate.","author":"Russel","journal-title":"J Am Soc Nephrol"},{"issue":"20","key":"joi260063r35","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1056\/NEJMe058035","article-title":"Chronic kidney disease in the elderly\u2014how to assess risk.","volume":"352","author":"Stevens","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"joi260063r36","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1093\/ndt\/gfad219","article-title":"Accuracy of GFR estimating equations based on creatinine, cystatin C or both in routine care.","volume":"39","author":"Fu","year":"2024","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"joi260063r37","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1681\/ASN.0000000000000128","article-title":"Accuracy of GFR estimating equations in patients with discordances between creatinine and cystatin C\u2013based estimations.","volume":"34","author":"Fu","year":"2023","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"joi260063r38","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1093\/ndt\/gfad007","article-title":"GFR estimated with creatinine rather than cystatin C is more reflective of the true risk of adverse outcomes with low GFR in kidney transplant recipients.","volume":"38","author":"Keddis","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"joi260063r39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.7326\/0003-4819-147-1-200707030-00004","article-title":"Cystatin C as a risk factor for outcomes in chronic kidney disease.","volume":"147","author":"Menon","year":"2007","journal-title":"Ann Intern Med"},{"issue":"2","key":"joi260063r40","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1681\/ASN.2011070663","article-title":"Filtration markers may have prognostic value independent of glomerular filtration rate.","volume":"23","author":"Tangri","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"joi260063r41","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1093\/ndt\/gfaf079","article-title":"High measured GFR as a predictor of all-cause mortality and cardiovascular disease in a prospective non-diabetic population cohort.","volume":"40","author":"Eriksen","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"joi260063r42","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.kint.2024.06.029","article-title":"Iohexol plasma clearance measurement protocol standardization for adults: a consensus paper of the European Kidney Function Consortium.","volume":"106","author":"Ebert","year":"2024","journal-title":"Kidney Int"},{"key":"joi260063r25","volume-title":"Regression Modeling Strategies","author":"Harrell","year":"2006"},{"key":"joi260063r27","doi-asserted-by":"crossref","DOI":"10.1201\/9780429492259","volume-title":"Flexible Imputation of Missing Data","author":"Van Buuren","year":"2018"},{"key":"joi260063r19","unstructured":"Iohexol clearance: patient investigation for external use. Article in Swedish. Karolinska University Laboratory. Accessed September 6, 2022. https:\/\/www.karolinska.se\/49eb42\/globalassets\/global\/2-funktioner\/funktion-kul\/klinisk-kemi\/dokument-kopplade-till-pta\/belastningar-anvisningar-och-protokoll\/iohexolclerarance-pt-undersokning-for-externt-bruk.pdf"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2850099\/jama_fu_2026_oi_260063_1786039304.85742.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:07:33Z","timestamp":1787065653000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2850099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,8,18]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2026.9639","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,18]]}}}